1971 360MEDLINK 712 North A2A Pharmaceuticals Abalone Bio Abreos Biosciences ACADIA Pharmaceuticals Accelero Biostructures Accuitis ACS Brightedge Fund ACT Genomics ActoBio Therapeutics Acquist Therapeutics Actinium Pharmaceuticals ADAM Adjuvance Technologies AEON Biopharma Aethlon Medical Ahead Therapeutics SL AIBIOS AIMM Therapeutics AiVita Biomedical Allen Institute For Brain Science Allogene Therapeutics Alpha Cancer Technologies Alpine Immune Sciences Alta Vista Advisors Altimmune American Gence Technologies Internationanl Amma Therapeutics Amnicell AMPsource Biopharma AMRA Medical Amygdala Neurosciences Anima Biotech Annexon Biosciences Antev Antidote Technologies Aon Risk Solutions Aposense Arcturus Therapeutics Ardigen Aristea Therapeutics Aspect Biosystems Aro Biotherapeutics AstraZeneca Attentive Therapeutics Auransa Aurora Bio Avail Bio Avails Medical AvantGen Therapeutics Avesthagen Limited Avisa Pharma AxeroVision AZTherapies Azure8 Bastion Biologics Bayer AG BCell Solutions Big4Bio Bilix Bill and Melinda Gates Foundation BioCentury Biocom Biolidics BioMarin Pharmaceutical BioMarker Strategies BioMotiv BioSuperior Technology Bioxceed Innovation Hub BioXcel Therapeutics Bipharm Bird Rock Bio BlackThorn Therapeutics Blaise Group International Bloom Science Boundless Bio  Brava Diagnostics Breakthrough Genomics BridgeBio Pharma BridGene Biosciences Bristol-Myers Squibb Company Bugworks Research Business France California Institute for Regenerative Medicine California Life Sciences Association Cambia Grove Canaccord Genuity Cantabio Pharmaceuticals Capella Therapeutics Cardiogas Technologies Caribou Biosciences Carmell Therapeutics Catalyst Pharmaceuticals Cell Care Therapeutics Celularity Century Therapeutics CerSci Therapeutics Cerevance Cesca Therapeutics Chubb Circle Pharma Circumvent City of Hope Clearbridge BSA Click Therapeutics Clinical and Laboratory Standards Institute Clinical Network Services (CNS)  CODA Biotherapeutics CohBar Comcast Common Pharma Contraline Correlia Biosystems Cortexyme Corvidia Therapeutics Cotinga Pharmaceuticals Courier Therapeutics Cue Biopharma Cydan II Cystic Fibrosis Foundation CytoDyn Cytonus Therapeutics Cytovia Therapeutics Da Volterra Dalriada Therapeutics Dalton Bioanalytics Daré Bioscience DealForma Deallus Consulting DeBiopharm International Deciduous Therapeutics Decoy Biosystems Deep Lens DelNova Delta-Fly Pharma Demuris Dia-beat-it DNALite Therapeutics DOTBIO Drusolv Therapeutics Dyadic International Dyve Biosciences EA Pharma Economic Development Agency Brandenburg Edesa Biotech Eidos Therapeutics Elektrofi Elevian Elex Biotech Eli Lilly and Company EngineBio Engrail Therapeutics Ensysce Biosciences EnterTroy Bio Epic Sciences Epilepsy Foundation Equillium Espero BioPharma ethris GmbH Eureka Therapeutics Evaluate Exicure Exotome Exxel Pharma Facile Therapeutics Fellow Health Fenologica Biosciences Fibrocell Science First Light Diagnostics Foresee Pharmaceuticals Fortress Biotech Galimedix Therapeutics Gaylan Bio Gel4Med GLAdiator Biosciences GlobalConnectWorks GlobalData GlyTech Golden Biotechnology Corp. Greenwich LifeSciences H.C. Wainwright & Company Halloran Consulting Group Halo Biosciences Haystack Sciences Heartseed Helixmith Co. Hercules Capital Hexagon Bio Hibernaid Histogen HIT Lab Honeylab Humanigen Hyaloric Biotech  Hygieia Biological Laboratories IACTA Pharmaceuticals Illumina Ventures Ilya Pharma ImmunoMet Therapeutics Immunophotonics Immupharma Impact Therapeutics Impel NeuroPharma IMV InCarda Therapeutics Incysus Therapeutics Informa InMed Pharmaceuticals Innofly Management Innovate Biopharmaceuticals Intabio Interface Biologics Interpace Diagnostics Group InterVenn Biosciences InveniAI Inversago Pharma Invictus Therapeutics Invivo Sciences ISOThrive Jaan Biotherapeutics JT Pharma Kedalion Therapeutics Kaléo Pharma Kelun Pharmaceuticals Kezar Life Sciences Kineta Kinoxis Therapeutics Kissei America

Kleo Pharmaceuticals KPI Therapeutics Kymeris Therapeutics Kyorin USA Lagunita BioSciences Landos Biopharma LaVoieHealthScience Leibniz Institute on Aging Leidos L.E.K. Consulting Lempo Therapeutics Lexent Bio LG Advisors LIPAC Oncology Locana Locust Walk Lonza Pharma & Biotech LSA Lung Therapeutics Lunit Lupa Bio Lynx Biosciences MacDougall Biomedical Communications MAIA Biotechnology Mammoth Biosciences Mandalmed MaveriX Oncology MaxCyte Mantra Bio Medsavana Membio Merck Metacrine Metcela MetVital Microbion MicroRadical 360 Miibio Mingsight Pharmaceuticals Mitsubishi Tanabe Pharma MMSC Molecular Theranostics Monash University Morphocell Technologies Morrison & Foerster MultiVir MUSC Foundation for Research Development Mycovia Pharmaceuticals Nammi Therapeutics Nanostics Nascent Biotech National Institutes of Health, NHLBI National Taiwan University College of Medicine NAUGEN Navidea BioPharmaceuticals Navigant Consulting Navigen Pharmaceuticals NB Health Laboratory NDA Group Nelum NeOnc Technologies  Neumentum NeuroBo Pharmaceuticals Neurocycle Therapeutics Neuroscience Trials Australia Neuroscientific Biopharmaceuticals New Orleans Business Alliance New York BIO New5win Nikon Instruments Nkarta Therapeutics North Carolina Biotechnology Center Novelogics Biotechnology Novotech Nucleus Network NuMedii NuvOx Pharma Okava Pharmaceuticals Omada Health Omicsway Oncobox Oncolytics Biotech Oncolyze Therapeutics Oncomatryx Biopharma OncoSenX Opiant Pharmaceuticals Opus Biotech Communications Oragenics Orion Biotechnology OrphoMed Orthopaedic Research and Education Foundation OrthoTrophix OxSonics Therapeutics OxStem Limited Pacific Western Bank Pacylex Pharmaceuticals Panacea Venture Panjab University PAION AG Paras Biopharmaceuticals Finland Oy Phanes Therapeutics PharmaDirections Phenomic AI Phosplatin Therapeutics Pivotal BioVenture Partners PRC Clinical Precision for Medicine Privo Technologies Promethera Biosciences Proteina Q Therapeutics Quadriga Biosciences Rafael Pharmaceuticals Rakuten Medical Japan K.K. Rejuvenation Technologies Retrotope Rezolute Riptide Bioscience Rock Health Ventures RubrYc Therapeutics SAB Biotherapeutics Sapience Therapeutics Satellos Bioscience Satsuma Pharmaceuticals SCIBAC Scribe Therapeutics Seelos Therapeutics SEngine Precision Medicine SENS Research Foundation Senti Biosciences Sentien Biotechnologies Serimmune SFA Therapeutics ShareVault Shifa Biomedia Corporation Shinkei Therapeutics Siragen Pharmaceuticals Sisu Pharma SmartPharma Therapeutics Sofinnova Ventures Spectrum Pharmaceuticals SpinalCyte, LLC Splash Pharmaceuticals Stanford Rock Center for Corporate Governance Stanford SPARK Program Stanford University Sterling Bay Stero Therapeutics STPI, NARLAbs Structure Based Design Summit Therapeutics Surrozen Symvivo Corporation SynDevRx Synthetic Biologics SyntheX Tampere University TargetGene Biotechnologies Technology Venture Commercialization TEGA Therapeutics Teikoku Pharma USA Tempo Therapeutics Terran Biosciences Terumo BCT The Money Channel NYC The University of Chicago The University of Texas MD Anderson TheraTarget ThinkCyte Thrombo Therapeutics Tiberend Strategic Advisors Tierra Biosciences TIGAR Health Torreya Tosk Traffic Therapeutics Tranquil Clinical Research Tranquis Therapeutics Trilogy Therapeutics Triursus Therapeutics TrovaGene True Bearing Diagnostics Tulane University School of Medicine TVAX Biomedical U.S. Pharmacopeial UC Davis-Office of Research Ultivue University of California, Davis University of California, San Francisco University of Colorado Anschutz Medical Campus University of Delaware University of Michigan University of Oslo University of Texas at Austin University of Texas, MD Anderson Cancer Center University of the Sunshine Coast Clinical Trials Centre University of Tsukuba University of Utah TVC Univfy Unnatural Products Valitor Valley Fever Solutions Valtari Bio Vaporox Varsona Pharmaceuticals Vasomune Therapeutics VelosBio Venture Valuation Vida Strategic Partners viDA Therapeutics Vigeo Therapeutics Viramal Vistara Biosciences VitriVax VM Oncology Vona Oncology Vybion Wenbli Therapeutics Wheelhouse Willis Towers Watson Wilson Sonsini Goodrich & Rosati xCella Biosciences Xenetic Biosciences Xoc Pharmaceuticals Xontogeny X-Therma Yiviva Zenith Epigenetics Zenopharm

*As of 10/22/2019

Below are the companies who have been nominated in each of three categories, "Early Stage Entrepreneurs", "Late Stage Leaders" and "Diagnostics and Beyond". Only one vote per email address will be counted. Read the official contest rules here. Don't forget to register for the BIO Investor Forum, happening October 22-23 in San Francisco! 

If you are interested in giving a company presentation, but missed the nominations window, you can apply to present here.

Nominees

Cancellations

Cancellation requests must be submitted in writing on or before September 18, 2019, (5:00 pm Central Time) to receive a refund. A $600 administrative fee will be deducted from all cancellation refunds. Approved refunds will be processed after the conference.

Cancellation requests received after September 18, 2019 will NOT be honored.  Email cancellation requests to Register@bio.org. Registration fees are not transferable to any other conference.

Substitutions

You may make changes to your record or transfer your registration to another individual by clicking on the URL provided in your confirmation email. This feature is available up until your name badge is printed on-site.

Membership Status

Your company must be a BIO Member in good standing on or before October 23, 2019 to receive the BIO Member Rate. If you'd like to consider membership, please visit our membership benefits page for more information.

Registration fees include access to all sessions, breakfasts, luncheons, and receptions. All attendees must be registered and wearing their name badge onsite to participate in conference activities. Registration may not be shared.

A government-issued photo ID (driver’s license or passport) is required at check-in. Badges will not be issued without proper identification.

For the purposes of registration for any BIO event, conference or meeting, the classification of a registrant as a research and development company, an industry service provider, an academic & technology licensing officer or a qualifying investor is subject to review by BIO. In its sole discretion, BIO reserves the right to make the determination of the proper classification of a registrant. Depending on this classification, an additional registration fee maybe required. BIO reserves the right to publish materials and restrict conference and/or partnering system access consistent with these determinations. Please note that BIO reserves the right to live tweet conference events, and questions asked by attendees at panels and sessions may be shared on social media.

---

Contact Business Development Registration

Customer Service Hours: 9:00 am – 5:00 pm Eastern Time, Monday-Friday
Email: register@bio.org
Telephone: +1 (202) 962-6655

Rachel Haurwitz, PhD, President and Chief Executive Officer, Caribou Biosciences, Inc.

October 19, 2016
12:30 p.m. - 1:25 p.m.

Rachel is a co-founder of Caribou Biosciences and has been President and CEO since its inception. She has a research background in CRISPR-Cas biology, and in 2014, she was named by Forbes Magazine to the "30 Under 30" list in Science and Healthcare. She is also a co-founder of Intellia Therapeutics where she is a member of the board of directors. Rachel is an inventor on several patents and patent applications covering multiple CRISPR-derived technologies, and she has co-authored scientific papers in high impact journals characterizing CRISPR-Cas systems. Rachel earned an A.B. in Biological Sciences from Harvard College, and received a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley.

 

Liam Ratcliffe, MD, PhD, Managing Director, New Leaf Venture Partners

October 19, 2016
10:00 a.m. - 10:55 a.m.

Liam Ratcliffe is a Managing Director at New Leaf Venture Partners, and concentrates on biopharmaceutical investing. Liam joined New Leaf in September 2008. Liam previously served as Senior Vice President and Development Head for Pfizer Neuroscience, as well as Worldwide Head of Clinical Research and Development. Additional positions during his 12 years at Pfizer included Vice President of Exploratory Development for the Mid West region (based in Ann Arbor, MI), and Head of Experimental Medicine at Pfizer’s Sandwich, UK Laboratories. As Head of Neurosciences, Liam was responsible for the development of several successful late-stage projects and marketed products, including Lyrica, Chantix and Geodon. In previous roles, he gained extensive experience in early drug development and translational research across multiple therapeutic areas, including inflammation, pain, cardiovascular disease, infectious diseases and genito-urinary medicine.

Liam began his career in the pharmaceutical industry in a medical marketing role at Roche in South Africa. He received his M.D. degree and Ph.D. degree in immunology from the University of Cape Town and his M.B.A. degree from the University of Michigan. Liam completed his internal medicine training and fellowship in Immunology at Groote Schuur Hospital and associated teaching hospitals in Cape Town, South Africa.

Liam also serves on various industry panels, including the Leadership Counsel of the University of Michigan Life Sciences Institute, the Advisory Council of the Keck Graduate Institute, the Life Sciences Advisory Panel of Frankel Consulting and the Pfizer External Advisory Panel for Ophthalmology, the AstraZeneca External Advisory Panel for Research & Development Strategy and Anti-Infectives.

Board Seats:

• Afferent Pharmaceuticals
• Aptinyx Inc.
• Arvinas, Inc.
• Calchan Holdings Limited
• Deciphera Pharmaceuticals, LLC
• Edge Therapeutics, Inc.
• Karus Therapeutics
• Unum Therapeutics Inc.

Notable Alumni Investments:

• Acadia Pharmaceuticals (NASDAQ: ACAD)
• Array BioPharma (NASDAQ: ARRY)
• Convergence Pharmaceuticals (Acquired by Biogen Idec)
• MEI Pharma (NASDAQ: MEIP)

 

Ryan Watts, PhD, Chief Executive Officer, Denali Therapeutics Inc.

October 18, 2016
12:30 p.m. - 1:25 p.m.

Ryan Watts is one of the co-founders of Denali Therapeutics and a member of the Board of Directors. He serves as the President and Chief Executive Officer. Ryan previously served as Director of the Department of Neuroscience at Genentech, where he was employed for 11 years. During his tenure there, he led the company’s entry into neuroscience, building a department and advancing multiple programs for neurological disease from discovery to clinical testing. Ryan’s own laboratory focused on drug discovery for Alzheimer’s disease and on understanding mechanisms of neurodegeneration guided by human genetics. Ryan is also a leader in the development of improved methods for delivering therapeutic antibodies across the blood-brain barrier. He obtained his B.S. from the University of Utah and his Ph.D. in biological sciences from Stanford University.

 

Below is a representative list of participating investment firms and sell side research analysts for the 2019 BIO Investor Forum.

3E Bioventures 3M Company AbbVie ABES Venture Partners Abingworth Management Accelerator Life Science Partners Acuris Partners Adjuvant Agent Capital Agilent Technologies Aleph Capital Alexandria Venture Investments Alignment Ventures Altamont Pharmaceutical Holdings ATEL Ventures Altitude Life Science Ventures Andreessen Horowitz Aquilo Capital Arch Venture Partners Arix Bioscience ARTIS Ventures Asahi Kasei America Asajes Medical Asajes Ventures Aspire Capital Asset Management Ventures Astellas Innovation Management  Astellas Pharma US Astellas Venture Management ATEL Ventures Atheneos Ventures AUGC Biofund Band of Angels Barbara Lavery Beacon Capital Biocoast Capital BioIdeations Biomark Capital BioPacific Investors Bios Partners Biotech Alliances International Black Horse Capital Bohe Angel Fund Borex Capital Boryung Holdings BOSON Capital Partners Brace Pharma Capital Brain Trust Accelerator Fund Bridge Bank BridgeBio Pharma Brookline Capital Markets BTIG Canadian Imperial Bank of Commerce Capital Family Office Cato BioVentures CEC Capital Cenova Capital Chaperone Investment China Grand CI Investments Cipla Cove Fund II Coventry Enterprises Cowin Capital Crosswave Management CRV CSC Leasing Dabar Investment Associates Dalton Investment Danaher Life Sciences Data Collective Venture Capital DAYLI Partners DCVC Bio Defta Partners DHVC DigiTx Partners Dolby Family Ventures Dorset Capital DoubleLine Capital Dynamk Capital East West Bank Eisai Emerson Collective Esousa Holdings FMG Ventures Fosun Private Equity F-Prime Capital Partners Fujifilm Diosynth Biotechnologies G4S Capital GE Ventures Genoa Ventures Global Neurohealth Ventures GreatPoint Ventures GreenSky Capital Grey Sky Venture Partners Hannol Ventures Hbm Partners HCM Healthcare Capital Management HEDA Ventures HealthCare Royalty Partners Helicase Venture Helix Ventures Hemi Ventures Hercules Capital Hermes Life Sciences Ventures H.I.G. Capital Hone Capital Iaso Ventures Illumina Accelerator Illumina Ventures Inbio Ventures In Capital INCJ Integral Group Integrium Intuitive IPF Partners

JHBio Johnson & Johnson Development Corporation Joyance Partners Julz Co Juvenile Diabetes Research Foundation (JDRF) KB Financial Group Kingsford Capital Management Kyoto University Innovation Capital Laguna Ventures Lam Research Landmark Angels Laurel Venture Capital LEO Pharma Life Science Angels Lilly Asia Ventures Lincoln Park Capital Lumira Ventures Lyfe Capital Lymo Ventures LYZZ Capital Advisors Matthews Asia Matthews International Capital Management Maywell Capital MDB Capital Group MedImmune Ventures Merck Milestone Capital Mitsui & Co. Global Investment Momentum Biotech MPM Capital MSQ Ventures MyBioGate Nan Fung Life Sciences NanoDimension NCL Technology Ventures New Enterprise Associates (NEA) Nomura Instinet Northern Light Venture Capital Novo Ventures (US) OCV Olive Tree Capital Oresund Capital OSF Healthcare Ventures Otsuka Pharmaceutical Co. Oxford Finance Palo Alto Investors Panacea Venture Healthcare Pappas Ventures Perseverance Capital Pharmstandard JSC Pivotal BioVenture Partners PoC Capital Premier Partners Presidio Partners Prevail Partners Primer Capital Qiming Venture Partners VSA Quadriga Biosciences Quan Capital RBV Capital Relentless Pursuit Partners Remiges Ventures Research Bridge Partners RHK Capital Roche Venture Fund Samsung Bioepis Samsung Venture Investment Sanderling Ventures Sandhill Angels Sanofi Santen Pharmaceutical Co. Santen Ventures Satter Medical Technology Partnership Science Futures Shanghai Henlius Biotech Shenzhen Salubris Pharmaceuticals Simcere Pharmaceutical Group Sinar Mas Technology Smilegate Investment Sofinnova Ventures SPRIM Ventures SR One StarLink Capital StartUp Health Steel Wolf Ventures Strathspey Crown Sumavision USA SWP Syzygy Therapeutics Taiho Ventures Taiwania Capital Takeda Ventures Talfinium Investments Tech Coast Angels The Benchmark Company The Leukemia & Lymphoma Society Tosoh USA TransPacific Venture Capital Partners Triple Ring Technologies Ultreum Capital V02 Global VantagePoint Capital Partners venBio Partners VentureSouq Vertex Venture Holdings Vivo Capital Voya Financial WARF Therapeutics Washington Research Foundation Center WBB Securities Westlake Ventures W Global Capital WI Harper Group Wu Capital Xeraya Capital Life Venture Y Combinator Yonjin Capital Yuhan USA ZGC Capital ZJ Future

*As of  10/18/2019

There are three types of registration for the BIO Investor Forum. Please choose your registration type:

General Registration

For companies, group packages, academic, government, nonprofit, presenting companies, discovery companies, and service providers. 

Investor Registration

Qualified investors can apply for complimentary registration to the conference. 

Media Registration

Valid press credentials include: Official photo identification from employing news agency, a by-lined story from employing news agency dated within the last six months, or a publication masthead listing you as an editorial contributor.

BIOTECH/PHARMA COMPANY

Corporations or other life sciences entities that use biotechnology or related technologies for research and development of therapeutic drugs, diagnostics, genomics, or digital therapeutics.

EMERGING INNOVATORS TRACK COMPANY (NEW) 

Corporations qualifying for the Emerging Innovators Track discounted rates include only the following: Emerging Innovators Track corporations are biotech and related companies that have cumulatively raised at least $9M, but less than $25M total through October 2019. For this event, Emerging Innovator Track companies must use biotechnology or related technologies to conduct or support research and development of drug products, diagnostics, or digital therapeutics intended for regulatory approval or already under regulatory review.  

DISCOVERY TRACK COMPANY

Corporations qualifying for the Discovery Track discounted rates include only the following: Discovery Track corporations are "pre-emerging" biotech and related companies, qualifying as seed and A-round companies that have raised since founding less than $9M total through October 2019. For this event, Discovery Track companies must use biotechnology or related technologies to conduct or support research and development of drug products, diagnostics, or digital therapeutics intended for regulatory approval or already under regulatory review.

INVESTORS

BIO events attract the most sophisticated investors in the life science community and provide a robust forum for this community to engage in the advancement of promising technologies that improve and save lives. BIO is pleased to provide complimentary registration to qualified investors under BIO’s revised investor policy.

Qualified investors are defined as institutional, private equity, angel and venture investors with funds on-hand, whose primary activity is direct investment in research and development companies (e.g., hedge fund, mutual fund, or venture fund). Equity research analysts from investment banking institutions and buy-side analysts also qualify as investors.

The fund name, portfolio type, and other helpful information is needed for BIO to process your registration appropriately. Receipt of complimentary registration for a prior year's event does not automatically qualify a registrant for complimentary registration in 2019. In cases where no information is attainable via investor relations databases and/or internet searches may be required to provide additional information. 

Organizations who apply for investor registration, that have a service providing component to their business model, such as investor relations, contract services, organizations or who host competitive events will be ineligible for complimentary investor registration. Should BIO discover undisclosed information about an organization's business model AFTER an application has been approved, it may be rescinded at BIO’s discretion.  Please contact register@bio.org for more information.

ACADEMIC/GOVERNMENT/NON-PROFIT

Attendees affiliated with accredited government or academic institution. Attendees must show proof through business card or ID on-site. To be eligible for the non-profit registration category, the attendee must show proof of working for an organization that has already received 501(c)(3) status from the Internal Revenue Service.

MEDIA REGISTRATION

Media registration is open to editors and reporters working full time for print, broadcast or web publications with valid press credentials. Information on advance media registration for the BIO Investor Forum will be available in June 2019.

SERVICE PROVIDERS/SUPPLIERS

Corporations or other for-profit entities that provide services or products to biotechnology and other companies. Service providers include investment and merchant bankers and representatives of law, accounting, consulting, contract manufacturers, active pharmaceutical ingredient manufacturers, contract research organizations, real estate development, and economic development organizations. Service providers cannot register with presenting companies unless approved by BIO and do not receive access to BIO One-on-One Partnering™.

For service providers to access the BIO One-on-One Partnering system, the organization must sponsor at a specific level. Contact sponsor@bio.org to receive more information from our Sales and Sponsorship team.

For the purposes of registration for any BIO event, conference or meeting, the classification of a registrant as a research and development company, academic & government or a qualifying investor is subject to review by BIO. In its sole discretion, BIO reserves the right to make the determination of the proper classification of a registrant. Depending on this classification, an additional registration fee maybe required. BIO reserves the right to publish materials and restrict conference and/or partnering system access consistent with these determinations..

Congratulations to the 2019 winners!

Early Stage Entrepreneur	Late Stage Leader	Diagnostics and Beyond

 

The Buzz of BIO contest provides an excellent opportunity for companies looking to make the connections needed to take their product to the next phase. Ten biotechs will be nominated in each of the three categories: Early Stage Entrepreneurs, Late Stage Leaders, and Diagnostics and Beyond. The companies with the most number of votes in each category at the end of the voting period will win a complimentary conference registration and company presentation, along with exposure to thousands of industry elites and potential investors. Please note that the contest is open to U.S. companies only.

What is the Buzz of BIO?

Buzz of BIO is a contest that recognizes U.S. based companies with groundbreaking, early stage technologies with the potential for improving our lives. Companies can submit in one of three categories (below) for a chance to win a complimentary Company Presentation and Registration at the BIO Investor Forum (a $6,500 value)!

What is a Company Presentation? 

Company Presentations are quick, 13-minute pitches for companies who are currently in or working toward clinical testing and regulated review. They help gain exposure for your company to business development executives, investors, research analysts, and more in BIO One-on-One Partnering™. Learn more about Company Presentations. 

To qualify for the Early Stage Entrepreneur Grand Prize, companies must be actively developing a therapeutic product intended for FDA review that addresses human health issues and have raised less than $25 million USD as of July 1, 2019; have been founded after 2016; and have most recently completed either a Seed or Series A financing round. Companies that have previously presented at the BIO Investor Forum are not eligible for the Early Stage Entrepreneur category but are welcome to apply under the Late Stage Leader category (if the company meets the minimum dollar requirements of the Late Stage Leader category).

To qualify for the Late Stage Leader Grand Prize, companies must be actively developing a therapeutic product intended for FDA review that addresses human health issues and have raised more than $25 million USD as of July 1, 2019 and have enrolled at least one patient in a company-sponsored clinical trial posted at https://clinicaltrials.gov/. 

To qualify for the Diagnostics and Beyond category, companies must be primarily focused in medical diagnostics, drug delivery, drug development tools, or digital health technologies. 

How Does the Contest Work?

There are two phases to the Buzz of BIO Contest: Nominations and Voting.

1. During the Nominations period, we will collect nominations and review them to ensure they qualify for one of the three categories listed above, and that they meet the guidelines outlined in the contest rules here.
2. During the Voting period, nominees are encouraged to promote their participation in the contest via social media, email, etc. in order to drive more votes for their company. The companies that receive the most votes in their respective category will earn the title of the "Buzz of BIO!"

Due to the complexities of international laws regarding contests, only U.S. residents who are 21 years of age or older are eligible to enter. View the Buzz of BIO Contest Rules.  

Questions about the Buzz of BIO contest? Please contact Emily Longvall at elongvall@bio.org.

Click here to download the full company presentation schedule.
 

For a regularly updated spreadsheet listing all presenting companies' names, therapeutic specialties, company descriptions and lead products in development, please click here.

Discovery and Patient Advocacy/Non-Profit Organizations

Company	News & Information	Presentation Date, Time, Location
	ActiveSite Pharmacetucials, Inc. Discovery | Website	Tuesday, October 20 9:45 AM Stockton
	Aegle Therapeutics Corporation Discovery | Website	Tuesday, October 20 11:15 AM Stockton
	Agilis Biotherapeutics Discovery | Website	Tuesday, October 20 1:45 PM Stockton
	AhR Pharmaceuticals, Inc. Discovery | Website	Wednesday, October 21 9:00 AM Stockton
	Amadix Discovery | Website	Tuesday, October 20 10:45 AM Stockton
	Amunix Discovery | Website	Tuesday, October 20 11:30 AM Balboa
	Antegrin Therapeutics, Inc. Discovery | Website	Tuesday, October 20 3:45 PM Stockton
	Aten Porus Lifesciences Discovery | Website	Tuesday, October 20 4:00 PM Stockton
	Aurora BioPharma, Inc. Discovery | Website	Tuesday, October 20 2:15 PM Balboa
	Avrygen Corporation Discovery | Website	Tuesday, October 20 10:15 AM Balboa
	Batu Biologics Discovery | Website	Wednesday, October 21 10:15 AM Hearst Webcast
	Bigfoot Biomedical Discovery | Website	Tuesday, October 20 4:45 PM Stockton
	BioCurity Holdings, Inc. Discovery | Website	Wednesday, October 21 9:15 AM Stockton
	BioMarker Strategies Discovery | Website	Tuesday, October 20 10:15 AM Stockton
	Biomay AG Discovery | Website	Tuesday, October 20 9:30 AM Stockton
Capella Therapeutics	Capella Therapeutics, Inc. Discovery | Website	Tuesday, October 20 9:45 AM Balboa
	Celltheon Discovery | Website	Tuesday, October 20 5:15 PM Stockton
	Cloud Pharmaceuticals Discovery | Website	Wednesday, October 21 2:00 PM Stockton
	Colby Pharmaceutical Company Discovery | Website	Tuesday, October 20; Wednesday, October 21 2:30 PM (Tue); 10:45 AM (Wed) Stockton
	Cormorant Pharmaceuticals Discovery | Website	Wednesday, October 21 11:00 AM Stockton
	Curza Discovery | Website	Tuesday, October 20 3:00 PM Balboa
	Cyclica Inc. Discovery | Website	Wednesday, October 21 1:45 PM Stockton
	ECBio Discovery | Website	Tuesday, October 20 11:30 AM Stockton
	Embera NeuroTherapeutics, Inc. Discovery | Website	Tuesday, October 20 2:15 PM Stockton
	Encycle Therapeutics Discovery | Website	Wednesday, October 21 2:15 PM Stockton
	Euclises Pharmaceuticals, Inc. Discovery | Website	Wednesday, October 21 9:30 AM Stockton
	Genome Profiling, LLC "GenPro" Discovery | Website	Wednesday, October 21 3:15 PM Balboa
	GRI Bio, Inc. Discovery | Website	Tuesday, October 20 11:15 AM Balboa
	Impel NeuroPharma Discovery | Website	Tuesday, October 20 3:30 PM Stockton
	INanoBio Inc Discovery | Website	Tuesday, October 20 10:30 AM Stockton
INmune Bio	INmune Bio Discovery | Website	Wednesday, October 21 8:30 AM Stockton
	Italian Trade Agency Non-Profit | Website	Tuesday, October 20 5:00 PM Balboa
	Ixchel Pharma LLC Discovery | Website	Tuesday, October 20 2:00 PM Stockton
	JDRF Patient Advocacy | Website	Wednesday, October 21 3:00 PM Balboa
	LA BioMed Non-Profit | Website	Tuesday, October 20 9:15 AM Stockton
	Laurent Pharmaceuticals Discovery | Website	Tuesday, October 20 4:15 PM Stockton
	Magnus Life Science Discovery | Website	Tuesday, October 20 11:45 AM Stockton
	Mediomics, LLC Di covery | Website	Tuesday, October 20 10:00 AM Stockton
	MedLumics S.L. Discovery | Website	Wednesday, October 21 1:30 PM Stockton
	Meryx, Inc. Discovery | Website	Wednesday, October 21 9:45 AM Stockton
	Metys Pharmaceuticals AG Discovery | Website	Wednesday, October 21 11:15 AM Stockton
	Microbial Robotics Discovery | Website	Tuesday, October 20 2:30 PM Balboa
	MiNDERA Corp. Discovery | Website	Tuesday, October 20 1:30 PM Balboa
	Monopar Therapeutics Discovery | Website	Tuesday, October 20 8:15 AM Stockton
	MultiVir Inc. Discovery | Website	Tuesday, October 20 10:30 AM Balboa
	MUNIN Corporation Discovery | Website	Wednesday, October 21 11:45 AM Stockton
	Nemucore Medical Innovations, Inc. Discovery | Website	Wednesday, October 21 11:30 AM Stockton
	NeuroGenetic Pharmaceuticals Discovery | Website	Tuesday, October 20 2:45 PM Stockton
Nocemia	Nocemia Discovery	Tuesday, October 20 3:30 PM Balboa
	Oncoceutics, Inc. Discovery | Website	Tuesday, October 20 8:30 AM Stockton
	PixarBio Corporation Discovery | Website	Tuesday, October 20 10:00 AM Balboa
	Portal Instruments Discovery | Website	Tuesday, October 20 5:00 PM Stockton
	Protein Dynamic Solutions, LLC Discovery | Website	Tuesday, October 20 8:00 AM Stockton
	Proventus Bio Discovery | Website	Tuesday, October 20 2:00 PM Balboa
	RDD Pharma Discovery | Website	Tuesday, October 20 9:15 AM Balboa
	Resilience Therapeutics, Inc. Discovery | Website	Wednesday, October 21 2:30 PM Stockton
	Second Genome Discovery | Website	Tuesday, October 20 8:45 AM Stockton
Sensor Pharmaceuticals, Inc.	Sensor Pharmaceuticals, Inc. Discovery	Tuesday, October 20 10:45 AM Balboa
	Silurian Pharmaceuticals Discovery | Website	Tuesday, October 20 9:00 AM Stockton
	SolaranRx, Inc. Discovery | Website	Wednesday, October 21 10:00 AM Hearst
	Susavion Biosciences, Inc. Discovery | Website	Wednesday, October 21 10:30 AM Stockton
	TaiwanJ Pharmaceuticals Discovery | Website	Tuesday, October 20 9:00 AM Balboa
	The Leukemia & Lymphoma Society Patient Advocacy | Website	Wednesday, October 21 8:15 AM Stockton
	The National MS Society/Fast Forward Patient Advocacy | Website	Tuesday, October 20 1:30 PM Stockton
	Thetis Pharmaceuticals LLC Discovery | Website	Tuesday, October 20 11:00 AM Balboa
	Trade Office of Ecuador in Los Angeles/Yachay Non-Profit | Website	Tuesday, October 20 11:30 AM Davidson
	Transparency Life Sciences, LLC Discovery | Website	Wednesday, October 21 2:45 PM Stockton
	Trigemina, Inc. Discovery | Website	Tuesday, October 20 3:15 PM Hearst Webcast
	Valley Fever Solutions Discovery | Website	Tuesday, October 20 3:45 PM Balboa
	Buzz of BIO Winner: Early Stage Entrepreneur Whole Biome, Inc. Discovery | Website	Tuesday, October 20 11:45 AM Balboa
	WinSanTor Discovery | Website	Tuesday, October 20 3:00 PM Hearst

 

Public and Private Companies

Company	News & Information	Presentation Date, Time, Location
	AbGenomics International, Inc. Private | Website	Wednesday, October 21 10:00 AM Balboa
	Adaptimmune ADAP-NASDAQ | Website	Tuesday, October 20 9:00 AM Fillmore Webcast
	Adjuvance Technologies Private | Website	Wednesday, October 21 3:30 PM Davidson
	AFFiRiS AG Private | Website	Wednesday, October 21 11:00 AM Balboa
	AgeneBio Private | Website	Wednesday, October 21 9:00 AM Balboa
	Amarantus BioScience Holdings, Inc. AMBS-OTCQX | Website	Tuesday, October 20 9:30 AM Fillmore Webcast
	Apogenix GmbH Private | Website	Tuesday, October 20 8:30 AM Davidson
	Aptose Biosciences Inc. APTO-NASDAQ; APS-TSX| Website	Tuesday, October 20 9:00 AM Davidson
	Armetheon Private | Website	Wednesday, October 21 10:30 AM Davidson
	ARMO BioSciences Private | Website	Tuesday, October 20 3:00 PM Davidson
	Atossa Genetics, Inc. ATOS-NASDAQ| Website	Tuesday, October 20 3:00 PM Fillmore
	Aurinia Pharmaceuticals AUPH-NASDAQ| Website	Wednesday, October 21 11:00 AM Fillmore Webcast
	Avelas Biosciences, Inc. Private | Website	Tuesday, October 20 3:30 PM Davidson
	Benitec Biopharma BLT-ASX | Website	Wednesday, October 21 2:30 PM Fillmore Webcast
	Berg Private | Website	Wednesday, October 21 1:30 PM Davidson
	Biocept BIOC-NASDAQ| Website	Wednesday, October 21 9:00 AM Fillmore Webcast
	Bionik Laboratories Corp. BNKL-OTCBB | Website	Wednesday, October 21 3:00 PM Fillmore Webcast
	Bio-Path Holdings, Inc. BPTH-NASDAQ| Website	Tuesday, October 20 3:30 PM Fillmore Webcast
	BriaCell Therapeutics Corp. BCTXF-OTCQB | Website	Tuesday, October 20 9:30 AM Hearst Webcast
	C3 Jian, Inc. Private | Website	Tuesday, October 20 9:30 AM Davidson
	Cantex Pharmaceuticals, Inc. Private | Website	Tuesday, October 20 10:30 AM Fillmore Webcast
	Catalyst Pharmaceuticals, Inc. CPRX-NASDAQ| Website	Wednesday, October 21 2:00 PM Davidson
	Celator Inc CPXX-NASDAQCM | Website	Wednesday, October 21 1:30 PM Hearst Webcast
	Cellectar Biosciences CLRB-NASDAQ | Website	Tuesday, October 20 1:30 PM Fillmore Webcast
	Cerecor Inc. CERC-NASDAQ | Website	Tuesday, October 20 5:00 PM Fillmore
	Buzz of BIO Winner: Late Stage Leader Cold Genesys, Inc. Private | Website	Wednesday, October 21 2:30 PM Davidson
	Comentis Private | Website	Wednesday, October 21 8:00 AM Balboa
	Complexa Private | Website	Wednesday, October 21 10:30 AM Balboa
	ContraFect CFRX-NASDAQ| Website	Tuesday, October 20 10:30 AM Hearst Webcast
	ContraVir Pharmaceuticals CTRV-NASDAQ| Website	Tuesday, October 20 11:30 AM Hearst Webcast
	Corbus Pharmaceuticals Holdings, Inc. CRBP-NASDAQ| Website	Wednesday, October 21 11:30 AM Fillmore Webcast
	Cortex Pharmaceuticals, Inc. CORX-OTCQB; CORX-NASDAQ Website	Tuesday, October 20 11:30 AM Fillmore Webcast
	Critical Outcome Technologies Inc. COT-TSXV; COTQF-OTCQB | Website	Tuesday, October 20 2:00 PM Fillmore
	Curis, Inc. CRIS-NASDAQ | Website	Wednesday, October 21 2:00 PM Fillmore Webcast
	DelMar Pharmaceuticals, Inc. DMPI-OTCQX | Website	Wednesday, October 21 3:00 PM Hearst Webcast
	DURECT Corporation DRRX-NASDAQ | Website	Wednesday, October 21 9:30 AM Fillmore Webcast
	EnGeneIC Ltd. Private | Website	Tuesday, October 20 4:00 PM Davidson
	Felicitex Therapeutics Private | Website	Tuesday, October 20 2:00 PM Davidson
	Fennec Pharmaceuticals FRX-TSX; FENCF-OTCQB | Website	Tuesday, October 20 5:00 PM Hearst
	Galmed Pharmaceuticals GLMD-NASDAQ| Website	Tuesday, October 20 2:00 PM Hearst
	GenSpera, Inc. GNSZ-OTCQB | Website	Wednesday, October 21 8:00 AM Hearst Webcast
	Geron Corporation GERN-NASDAQ | Website	Wednesday, October 21 8:30 AM Hearst Webcast
	Glide Technologies Private | Website	Tuesday, October 20 4:00 PM Balboa
	Global Blood Therapeutics GBT-NASDAQ | Website	Wednesday, October 21 2:00 PM Hearst Webcast
	Histogenics Corporation HSGX-NASDAQ | Website	Tuesday, October 20 4:00 PM Hearst Webcast
	ImmunGene, Inc. Private | Website	Tuesday, October 20 4:30 PM Davidson
	KaloBios Pharmaceuticals, Inc. KBIO-NASDAQ | Website	Tuesday, October 20 8:00 AM Hearst Webcast
	KineMed, Inc. Private | Website	Tuesday, October 20 4:30 PM Balboa
	Makindus, Inc. Private | Website	Wednesday, October 21 3:30 PM Fillmore
	Mast Therapeutics, Inc. MSTX-NYSE MKT | Website	Tuesday, October 20 4:30 PM Hearst
	Matinas BioPharma Holdings, Inc. MTNB-OTCQB | Website	Tuesday, October 20 11:00 AM Hearst Webcast
	MAX BioPharma Private | Website	Tuesday, October 20 2:30 PM Hearst
	MEI Pharma, Inc. MEIP-NASDAQ | Website	Wednesday, October 21 9:00 AM Hearst Webcast
	Moleculera Labs Private | Website	Wednesday, October 21 8:30 AM Fillmore
	Navidea Biopharmaceuticals NAVB-NYSE MKT | Website	Wednesday, October 21 11:30 AM Hearst Webcast
	Neos Therapeutics NEOS-NASDAQ| Website	Tuesday, October 20 4:30 PM Fillmore Webcast
	Newron Pharmaceuticals SpA NWRN-SIX | Website	Wednesday, October 21 3:30 PM Hearst
	Nicox SA COX-Euronext Paris | Website	Tuesday, October 20 10:00 AM Fillmore Webcast
	Nimbus Therapeutics Private | Website	Tuesday, October 20 10:30 AM Davidson
	Nuvo Research, Inc. NRI-TSX | Website	Wednesday, October 21 11:30 AM Balboa
	Ocera Therapeutics, Inc. OCRX-NASDAQ| Website	Wednesday, October 21 2:30 PM Hearst Webcast
	OncoCyte Corporation Private| Website	Tuesday, October 20 1:30 PM Davidson
	Oncolytics ONCY-NASDAQ| Website	Wednesday, October 21 10:30 AM Hearst Webcast
	OncoSec Medical, Inc. ONCS-NASDAQ| Website	Wednesday, October 21 9:30 AM Hearst
	Opexa Therapeutics OPXA-NASDAQ| Website	Wednesday, October 21 10:00 AM Fillmore Webcast
	Oxigene, Inc. OXGN-NASDAQ| Website	Tuesday, October 20 4:00 PM Fillmore Webcast
	PCI Biotech PCIB-OSE | Website	Wednesday, October 21 10:00 AM Stockton
	Probiodrug PBD-Euronext | Website	Tuesday, October 20 8:00 AM Fillmore
	Pronutria Biosciences Private | Website	Wednesday, October 21 3:00 PM Stockton
	Protagonist Therapeutics, Inc. Private | Website	Tuesday, October 20 8:30 AM Balboa
	Protein Sciences Private | Website	Wednesday, October 21 11:30 AM Davidson
	Pulmatrix PULM-NASDAQ| Website	Tuesday, October 20 11:00 AM Fillmore Webcast
	Rebiotix, Inc. Private | Website	Tuesday, October 20 10:00 AM Hearst
	Relburn-Metabolomics, Inc. Private | Website	Wednesday, October 21 9:30 AM Balboa
	Relmada Therapeutics RLMD-OTCQB | Website	Wednesday, October 21 10:30 AM Fillmore Webcast
	Resverlogix Corp. RVX-TSX | Website	Wednesday, October 21 11:00 AM Davidson
	Rexahn Pharmaceuticals RNN-NYSE MKT | Website	Tuesday, October 20 2:30 PM Fillmore Webcast
	RuiYi Private | Website	Wednesday, October 21 1:30 PM Balboa
	RXi Pharmaceuticals Corporation RXII-NASDAQ| Website	Wednesday, October 21 1:30 PM Fillmore Webcast
	Savara Private | Website	Tuesday, October 20 11:00 AM Davidson
	Silver Creek Pharmaceuticals, Inc. Private | Website	Tuesday, October 20 3:00 PM Stockton
	Spectrum Pharmaceuticals SPPI-NASDAQ| Website	Wednesday, October 21 2:30 PM Balboa
	Sutro Biopharma Private | Website	Tuesday, October 20 2:30 PM Davidson
	Symic Biomedical Private | Website	Wednesday, October 21 3:30 PM Stockton
	Therabron Therapeutics, Inc. Private | Website	Wednesday, October 21 8:30 AM Davidson
	Thrasos Therapeutics, Inc. Private | Website	Tuesday, October 20 9:00 AM Hearst
	Tokai Pharmaceuticals, Inc. TKAI-NASDAQ| Website	Wednesday, October 21 11:00 AM Hearst Webcast
	True North Therapeutics, Inc. Private | Website	Tuesday, October 20 10:00 AM Davidson
	Twist Bioscience, Corp Private | Website	Wednesday, October 21 2:00 PM Balboa
	Tyrogenex Private | Website	Wednesday, October 21 9:30 AM Davidson
	ViaCyte Private | Website	Tuesday, October 20 3:30 PM Hearst
	Viking Therapeutics, Inc. VKTX-NASDAQ| Website	Tuesday, October 20 1:30 PM Hearst Webcast
	Xcovery Private | Website	Wednesday, October 21 3:00 PM Davidson
	Xeris Pharmaceuticals, Inc. Private | Website	Tuesday, October 20 8:30 AM Hearst
	Zynerba Pharmaceuticals ZYNE-NASDAQ | Website	Tuesday, October 20 8:30 AM Fillmore Webcast

 

Accurate as of 11/1/2015

Now accepting applications for the 2020 BIO Investor Forum.

Companies interested in presenting must have a clear R&D focus, with a pipeline involving biotechnology therapeutics, diagnostics, genomics, digital health or platform technologies. Service providers will not be considered. For questions about company presentations, please read our FAQ here.

Presenting company classifications include:

BIOTECH/PHARMA COMPANY:  Corporations or other entities that use biotechnology or related technologies for research and development of products or information.

DISCOVERY TRACK COMPANY:  Corporations qualifying for the Discovery Track rates include only the following: Discovery Track corporations are "pre-emerging" biotech companies, qualifying as seed and A-round companies that have raised since founding less than $9M total through October 2019. For this event, Discovery Track companies must use biotechnology or related technologies to conduct or support research and development of drug products, diagnostics, or digital therapeutics intended for regulatory approval or already under regulatory review.

EMERGING INNOVATORS TRACK COMPANY (NEW):  Corporations qualifying for the Emerging Innovators Track rates include only the following: Emerging Innovators Track corporations are biotech companies that have cumulatively raised at least $9M, but less than $25M total through October 2019. For this event, Emerging Innovator Track companies must use biotechnology or related technologies to conduct or support research and development of drug products, diagnostics, or digital therapeutics intended for regulatory approval or already under regulatory review.  

 Apply Here

Learn best practices on how to refine your presentation deck and pitch to partners. Download our series of short biotech-focused video lessons.